Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis

This study has been completed.
Information provided by (Responsible Party):
Juliana Silva, Brasilia University Hospital Identifier:
First received: June 20, 2011
Last updated: June 8, 2015
Last verified: June 2015

The purpose of this study is to determine whether miltefosine is effective in the treatment of mucosal leishmaniasis compared to meglumine antimoniate, the standard treatment.

Condition Intervention Phase
Leishmaniasis, Mucocutaneous
Drug: Miltefosine
Drug: Standard Treatment Meglumine antimoniate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis at Federal District, Brazil

Resource links provided by NLM:

Further study details as provided by Brasilia University Hospital:

Primary Outcome Measures:
  • Cure [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Re-epithelizations of mucosal ulcers or regression of symptoms

Secondary Outcome Measures:
  • Adverse effects [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    laboratory tests of blood, kidney, liver and cardiac functions, partients will be asked about nausea, vomiting, diarrhea, myalgia, or other symptoms

Enrollment: 40
Study Start Date: July 2009
Study Completion Date: December 2014
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standard Treatment
Meglumine antimoniate as recommended by the Brazilian Ministry of Health
Drug: Standard Treatment Meglumine antimoniate
20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
Other Name: pentavalent antimonial
Experimental: Tested Intervention
Miltefosine as the tested intervention
Drug: Miltefosine
1 Capsule of 50mg, taken orally 2 times a day for 28 days
Other Name: Impavido

Detailed Description:

Mucosal leishmaniasis is a rare form of the disease, that affects only 6% of the patients with cutaneous leishmaniasis in the New World. It causes deformities and may be lethal if not treated. It is part of the neglected tropical diseases because on the past sixty years there was few progress regarding other treatment options or improvement at quality of life of its patients. Also, there was little interest from the pharmaceutical industry and government authorities to develop new researches. The standard treatment, meglumine antimoniate, is toxic, invasive, requires trained personnel and has many adverse effects and restrictions. On the other hand, miltefosine is the first oral drug to demonstrate efficacy against mucocutaneous leishmaniasis. Few clinical trials have being performed in Central and South American countries, but so far, just one involved mucosal leishmaniasis patients, and compared miltefosine to amphotericin B. None studies comparing its efficacy to the standard treatment have being done.


Ages Eligible for Study:   12 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of mucosal leishmaniasis
  • Not previously treated, or last treatment must have occurred more than 6 months before the enrollment on the study
  • Use of contraceptive method, if female on child bearing age
  • Sign the agreement and consent form

Exclusion Criteria:

  • Previous leishmanicidal treatment on the past 6 months before the enrollment on the study
  • Electrocardiogram abnormalities on the pretreatment exams
  • Previous kidney, liver and/or heart diseases
  • Diabetes Mellitus
  • Hypersensitivity to miltefosine or meglumine antimoniate
  • Pregnant women or breastfeeding mothers
  • Hiv patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01377974

Brasilia University Hospital
Brasilia, DF, Brazil, 70910-900
Sponsors and Collaborators
Brasilia University Hospital
Principal Investigator: Juliana SF Silva, MD University of Brasilia
Study Chair: Raimunda NR Sampaio, PhD University of Brasilia
  More Information

No publications provided

Responsible Party: Juliana Silva, Dr. Juliana Silva, Brasilia University Hospital Identifier: NCT01377974     History of Changes
Other Study ID Numbers: MILTHUB
Study First Received: June 20, 2011
Last Updated: June 8, 2015
Health Authority: Brazil: National Committee of Ethics in Research

Keywords provided by Brasilia University Hospital:
Mucocutaneous Leishmaniasis
meglumine antimoniate

Additional relevant MeSH terms:
Leishmaniasis, Mucocutaneous
Euglenozoa Infections
Leishmaniasis, Cutaneous
Parasitic Diseases
Protozoan Infections
Skin Diseases
Skin Diseases, Infectious
Skin Diseases, Parasitic
Meglumine antimoniate
Anti-Infective Agents
Antifungal Agents
Antineoplastic Agents
Antiparasitic Agents
Antiprotozoal Agents
Contrast Media
Diagnostic Uses of Chemicals
Pharmacologic Actions
Therapeutic Uses processed this record on October 06, 2015